CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

X4 Pharmaceuticals Inc's Total Debt to Equity

XFOR's quarterly Total Debt to Equity and Total Debt, Equity growth


In the first quarter 2024 X4 Pharmaceuticals Inc did not have Total Debt.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved the lowest Total Debt to Equity in the first quarter 2024. While total ranking remained the same in the first quarter 2024 compared to the previous quarter at no. .

Explain Debt to Equity Ratio?
What is the structure of XFORīs Total Debt?
How valuable is the XFORīs Equity?


XFOR Total Debt to Equity (Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -98.6 % 9.29 % 124.57 % 3.95 % 14.96 %
Y / Y Total Debt Change - - -91.12 % -83.78 % 65.41 %
Total Debt to Equity MRQ - - 0.01 0.01 0.02
XFOR's Total Ranking # # # # #
Seq. Equity Change -98.47 % 0.09 % 30.69 % -30.22 % 19.73 %
Seq. Total Debt Change - - 37.91 % -57.87 % -91.01 %



Total Debt to Equity first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Total Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
X4 Pharmaceuticals Inc's Equity $ 1 Millions Visit XFOR's Balance sheet
X4 Pharmaceuticals Inc's Total Debt $ 0 Millions Visit XFOR's Balance sheet
Source of XFOR's Sales Visit XFOR's Sales by Geography


Cumulative X4 Pharmaceuticals Inc's Total Debt to Equity

XFOR's Total Debt to Equity for the trailling 12 Months

XFOR Total Debt to Equity

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -98.6 % 9.29 % 124.57 % 3.95 % 14.96 %
Y / Y Total Debt TTM Growth - - -91.12 % -83.78 % 65.41 %
Total Debt to Equity TTM 0.01 0.01 0.07 0.12 0.13
Total Ranking TTM
Seq. Equity TTM Growth -98.47 % 0.09 % 30.69 % -30.22 % 19.73 %
Seq. Total Debt TTM Growth - - 37.91 % -57.87 % -91.01 %


On the trailing twelve months basis During the twelve months ending I Quarter 2024 X4 Pharmaceuticals Inc did not have Total Debt .
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry XFOR recorded the lowest Total Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 3.

Explain Debt to Equity Ratio?
What is the structure of XFORīs Total Debt?
How valuable is the XFORīs Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 0
Within the Market #


trailing twelve months Total Debt to Equity Statistics
High Average Low
0.31 0.09 0
(Dec 31 2018)   (Sep 30 2021)




Companies with similar Total Debt to Equity in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Total Debt to EquityMar 31 2024 MRQ Total DebtMar 31 2024 MRQ Equity

Date modified: 2024-05-08T15:34:55+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com